FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.439 USD
-0.0091 (-2.07%)
Dr. Garo H. Armen Ph.D.
Healthcare
Biotechnology
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0001022899
US74365N2027
74365N103
149 Fifth Avenue
212 994 8200
US
1
Apr 27, 2021
Dr. Garo H. Armen Ph.D.
Co-Founder & Executive Chairman of the B...
0
1953
Dr. Alexander Kenneth Arrow C.F.A., M.D.
Chief Financial Officer & Secretary
150k
1971
Dr. Andrew Slee Ph.D.
Chief Operating Officer
0
1950
Dr. Robert Benjamin Stein M.D., Ph.D.
Chief Medical Officer & Director
0
1951
As of December 31, 2024, the total employee count stands at 1, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.